PMID- 20578198
OWN - NLM
STAT- MEDLINE
DCOM- 20100811
LR  - 20211020
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 85
IP  - 8
DP  - 2010 Aug
TI  - Long term follow-up of allogeneic stem cell transplantation in patients with 
      myelodysplastic syndromes using busulfan, cytosine arabinoside, and 
      cyclophosphamide.
PG  - 579-83
LID - 10.1002/ajh.21761 [doi]
AB  - We report here the 10-year follow-up of 86 patients who underwent allogeneic stem 
      cell transplantation (ASCT) for myelodysplastic syndrome (MDS). All patients 
      received the busulfan, cytosine arabinoside, and cyclophosphamide (BAC) 
      preparative regimen which consisted of busulfan 16 mg/kg, cytosine arabinoside 8 
      g/m(2) IV, and cyclophosphamide 120 mg/kg IV. Fifty-nine patients (69%) had de 
      novo MDS; 26 (30%) had secondary MDS (treatment related), and one had a preceding 
      aplastic anemia which progressed to MDS before transplant. Cytogenetics (80 
      patients) was classified as good (34%), intermediate (17%), or poor (42%). With a 
      median follow-up for survivors of 124 months, the 10-year Kaplan-Meier estimates 
      for overall survival (OS) was 43% (95% confidence interval [CI]: 31-53%). 
      Cumulative nonrelapse mortality (NRM) and relapse was 43% (95% CI: 32-54%) and 
      19% (95% CI: 11-27%), respectively. No patient relapsed after 2 years. In 
      patients with RAEB-T/AML, 10-year relapse-free survival (RFS), relapse, and NRM 
      was 36%, 36%, and 27%, respectively. Younger age (P = 0.05), human leukocyte 
      antigen (HLA) match (P = 0.002), good risk cytogenetics (P = 0.008), and having a 
      related donor (P = 0.03) significantly improved overall and RFS in the 
      multivariable analysis. The long-term follow-up of patients receiving the BAC 
      regimen with ASCT in this study indicated durable relapse-free and OS with 
      acceptable toxicity in this group of patients with high-risk features.
CI  - (c) 2010 Wiley-Liss, Inc.
FAU - Atallah, Ehab
AU  - Atallah E
AD  - Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwuakee, Wisconsin 
      53226, USA. eatallah@mcw.edu
FAU - Abrams, Judith
AU  - Abrams J
FAU - Ayash, Lois
AU  - Ayash L
FAU - Bentley, Gail
AU  - Bentley G
FAU - Abidi, Muneer
AU  - Abidi M
FAU - Ratanatharathorn, Voravit
AU  - Ratanatharathorn V
FAU - Uberti, Joseph
AU  - Uberti J
LA  - eng
GR  - P30 CA022453/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Myeloablative Agonists)
RN  - 04079A1RDZ (Cytarabine)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - G1LN9045DK (Busulfan)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Busulfan/administration & dosage/*therapeutic use
MH  - Cyclophosphamide/administration & dosage/*therapeutic use
MH  - Cytarabine/administration & dosage/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Graft vs Host Disease/mortality/prevention & control
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Infections/mortality
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Myeloablative Agonists/administration & dosage/*therapeutic use
MH  - Myelodysplastic Syndromes/mortality/*surgery
MH  - Postoperative Complications/mortality
MH  - Recurrence
MH  - Retrospective Studies
MH  - *Stem Cell Transplantation
MH  - *Transplantation Conditioning
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC3800118
MID - NIHMS513633
COIS- Conflict of interest: Nothing to report
EDAT- 2010/06/26 06:00
MHDA- 2010/08/12 06:00
PMCR- 2013/10/19
CRDT- 2010/06/26 06:00
PHST- 2010/06/26 06:00 [entrez]
PHST- 2010/06/26 06:00 [pubmed]
PHST- 2010/08/12 06:00 [medline]
PHST- 2013/10/19 00:00 [pmc-release]
AID - 10.1002/ajh.21761 [doi]
PST - ppublish
SO  - Am J Hematol. 2010 Aug;85(8):579-83. doi: 10.1002/ajh.21761.